Please ensure Javascript is enabled for purposes of website accessibility

Good News for Vivus and Arena

By Dave Williamson and Brenton Flynn - Nov 23, 2012 at 3:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Aetna's recent insurance clinical policy bulletin update should boost sales.

Even after beating its competitors to market with its weight loss drug Qsymia, Vivus (VVUS) sales have left investors wanting. At roughly $160 per month, the price was causing a 30% abandonment rate with patients. But now, a revised Aetna (AET) clinical policy bulletin deemed weight loss drugs Qsymia and Arena Pharmaceutical's (ARNA) Belviq as medically necessary, potentially expanding coverage, and consequently boosting both initial sales and continued use of the drug for many patients. The announcement has caused share prices of several drug makers in this space to jump.

Editors Note: In this video, it is implied that drugs by GlaxoSmithKline and Pfizer were also added to Aetna's clinical policy bulletin, when they were already listed. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.06 (-0.81%) $0.36
Aetna Inc. Stock Quote
Aetna Inc.
AET
Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
ARNA
VIVUS, Inc. Stock Quote
VIVUS, Inc.
VVUS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.